Dermal fillers

Licensed as Class III medical devices, product by product; this page reads Allergan’s four and Restylane’s two. Health Canada lists Juvéderm Volbella with Lidocaine on licence 90956, Voluma with Lidocaine on 77899, Volift with Lidocaine on 93534 and Volux on 102650, and under Q-Med, Restylane Kysse on 95283 and Restylane Lyft Lidocaine on the Restylane family licence 1934; other hyaluronic acid fillers sold in Canada hold licences of their own under their makers’ names. A licence records Health Canada’s review of the device against its safety and effectiveness requirements for the use filed; it does not establish every benefit, area or duration a clinic advertises.Health Canada · MDALL licences 90956, 77899, 93534, 102650, 95283 and 1934

GST or HST applies to taxable cosmetic treatments: 13% in Ontario, 5% where only GST is charged. The clinic prices here are before tax. A treatment for a medical or reconstructive purpose may be exempt when it meets the applicable health-care exemption’s conditions, including who supplies or performs the service; its purpose alone does not establish an exemption.Excise Tax Act · s. 165, Sch. V Pt. II ss. 1, 1.1, 1.2 and 5 to 7, Sch. VIII

A physician, a nurse practitioner, or a nurse working under one. The College of Nurses of Ontario’s guideline on aesthetic services (2026) states that injecting neuromodulators and dermal fillers involves two controlled acts, so an RN or RPN needs an order or directive from a nurse practitioner or physician, while nurse practitioners are autonomous. Under the College of Physicians and Surgeons of Ontario’s delegation policy, a physician who delegates remains accountable. Other provinces set their own rules.CNO · Aesthetic services, practice guideline (2026) · CPSO · Delegation of controlled acts

Not in the figures above. Every number is read from the product’s own pivotal study, run by its maker, Allergan or Galderma, for its US approval and reported in the directions for use the FDA reviewed. The raters were blind to treatment and each study had a comparison, but the maker chose the scale, ran the study and wrote it up. This page cites no trial run by anyone else.Allergan Volbella 2021 §7, Voluma 2013 §7, Vollure 2023 §7, Volux 2023 §7 · Galderma Kysse 2020 §7, Lyft 2018 MA-1400-05

Yes, with hyaluronidase, an enzyme that breaks down hyaluronic acid. The Juvéderm directions list hyaluronidase injection among the treatments when gel blocks a vessel; Kysse’s list it among the treatments reported for such events. No hyaluronidase product holds a Canadian drug identification number on its own; a 2021 survey of Canadian plastic surgeons reports it obtained through Health Canada’s Special Access Program or compounded by a pharmacy. The enzyme has side effects of its own. Two US hyaluronidase labels, which list no filler use among their indications, report injection-site reactions, such as redness and pain, most often and allergic reactions in under 0.1% of people, rarely anaphylactic-like, and rule it out for anyone hypersensitive to it. Whether to dissolve, and when, is the injector’s assessment.Allergan Volbella 2021 instruction 18, Voluma 2013 instruction 13 · Galderma Kysse 2020 §6.B · Olaiya 2021, PMID 35990397 · Health Canada · DPD · Hylenex recombinant 2024 and Amphadase 2024 US labels §§ 1, 4 and 6